Stempoint Capital LP holds a focused book of 70 stocks worth $520.3M as of Q1 2026 (disclosed May 18, 2026, a ~48-day 13F lag). This quarter they opened Enliven Therapeutics Inc and trimmed Abivax Sa-ADR. Their largest long position is Scholar Rock Holding Corp at 10% of the equity book. They also disclosed $525K in put options (a bearish bet) and $1.6M in call options (bullish), shown separately below and excluded from the equity book. Cloning the disclosed picks since 2024 would be +29% (+11.0%/yr). That is a simulation of the disclosed long book, not audited returns.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1952142/holdings"
Use Arkolith to show STEMPOINT CAPITAL LP's latest holdings, largest changes, and filing provenance.
The reported book (valued from quarter-end) returned +59.6%, a 30.1-point gap that is the cost of the ~48-day 13F disclosure lag a real follower can't avoid.
Growth of $10,000 cloning Stempoint Capital LP's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~48 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Stempoint Capital LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| MORGAN STANLEY | 80 / 70 | $15.2B |
| UBS Group AG | 80 / 70 | $6.1B |
| GEODE CAPITAL MANAGEMENT, LLC | 79 / 70 | $19.2B |
| STATE STREET CORP | 77 / 70 | $40.6B |
| BlackRock, Inc. | 76 / 70 | $70.9B |
| GOLDMAN SACHS GROUP INC | 76 / 70 | $7.7B |
| BNP PARIBAS FINANCIAL MARKETS | 76 / 70 | $1.2B |
| JPMORGAN CHASE & CO | 74 / 70 | $18.2B |
Ranked by how many of Stempoint Capital LP's top 70 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Scholar Rock Hldg Corp COM | $50.9M | 1.04M | 9.8% | ▲+17% Added · +149K sh | |
| 2 | Abivax Sa SPONSORED ADS | $34.9M | 313.8K | 6.7% | ▼−20% Reduced · −78K sh | |
| 3 | Syndax Pharmaceuticals Inc COM | $28.4M | 1.22M | 5.5% | ▼−9.2% Reduced · −124K sh | |
| 4 | Revolution Medicines Inc COM | $27.4M | 281.6K | 5.3% | ▲+354% Added · +220K sh | |
| 5 | Immunovant Inc COM | $18.5M | 746.5K | 3.6% | ▲+16% Added · +102K sh | |
| 6 | Praxis Precision Medicines I COM NEW | $18.1M | 56.3K | 3.5% | ▲+167% Added · +35K sh | |
| 7 | MBX Biosciences Inc COM | $14.9M | 499.5K | 2.9% | ▲+536% Added · +421K sh | |
| 8 | Mineralys Therapeutics Inc COM | $14.4M | 533.4K | 2.8% | ▲+84% Added · +243K sh | |
| 9 | Enliven Therapeutics Inc COM | $14.2M | 363.4K | 2.7% | ▲New New position | |
| 10 | CG Oncology Inc COM | $13.9M | 205.6K | 2.7% | ▲New New position | |
| 11 | Biohaven Ltd COM | $13.5M | 1.59M | 2.6% | ▲New New position | |
| 12 | Surrozen Inc COM NEW | $13.5M | 525.6K | 2.6% | ▼−15% Reduced · −94K sh | |
| 13 | Roivant Sciences Ltd SHS | $10.7M | 385.8K | 2.1% | ▼−60% Reduced · −581K sh | |
| 14 | Eyepoint Inc COM NEW | $10.5M | 810.8K | 2.0% | ▲+129% Added · +457K sh | |
| 15 | Arcutis Biotherapeutics Inc COM | $9.7M | 413.8K | 1.9% | ▲+84% Added · +189K sh | |
| 16 | Structure Therapeutics Inc SPONSORED ADS | $9.7M | 200.3K | 1.9% | ▼−43% Reduced · −151K sh | |
| 17 | Amylyx Pharmaceuticals Inc COM | $9.3M | 669.7K | 1.8% | ▲+18% Added · +105K sh | |
| 18 | Dyne Therapeutics Inc COM | $9.2M | 506.1K | 1.8% | ▼−39% Reduced · −329K sh | |
| 19 | Edgewise Therapeutics Inc COM | $9.2M | 290.9K | 1.8% | ▼−19% Reduced · −70K sh | |
| 20 | Cytokinetics Inc COM NEW | $8.5M | 129.6K | 1.6% | ▼−12% Reduced · −17K sh | |
| 21 | Spyre Therapeutics Inc COM NEW | $8.5M | 167.6K | 1.6% | ▲+418% Added · +135K sh | |
| 22 | Denali Therapeutics Inc COM | $8.2M | 426.6K | 1.6% | ▲+1.8% Added · +8K sh | |
| 23 | Xenon Pharmaceuticals Inc COM | $8.2M | 140.8K | 1.6% | ▼−60% Reduced · −208K sh | |
| 24 | Celldex Therapeutics Inc New COM NEW | $8.1M | 254.3K | 1.6% | ▲New New position | |
| 25 | Protagonist Therapeutics Inc COM | $7.6M | 72.6K | 1.5% | ▲+22% Added · +13K sh | |
| 26 | Tyra Biosciences Inc COM | $7.4M | 193.2K | 1.4% | ▲New New position | |
| 27 | Dianthus Therapeutics Inc COM | $7.2M | 85.5K | 1.4% | ▲+7.8% Added · +6K sh | |
| 28 | Celcuity Inc COM | $6.9M | 60.1K | 1.3% | ▼−49% Reduced · −58K sh | |
| 29 | Definium Therapeutics Inc COM SHS | $6.2M | 325.5K | 1.2% | ▲New New position | |
| 30 | Bioage Labs Inc COM | $5.9M | 338.7K | 1.1% | ▲New New position | |
| 31 | Newamsterdam Pharma Company ORDINARY SHARES | $5.8M | 180.7K | 1.1% | ▲+147% Added · +108K sh | |
| 32 | Acadia Pharmaceuticals Inc COM | $5.4M | 242.6K | 1.0% | ▲New New position | |
| 33 | Assembly Biosciences Inc COM NEW | $5.1M | 185.4K | 1.0% | ▲+18% Added · +29K sh | |
| 34 | Alumis Inc COM | $5.1M | 229.6K | 1.0% | ▲New New position | |
| 35 | Nurix Therapeutics Inc COM | $4.9M | 315.2K | 0.9% | ▲New New position | |
| 36 | Zura Bio Ltd CLASS A ORD SHS | $4.5M | 753.5K | 0.9% | ▲New New position | |
| 37 | Evommune Inc COM SHS | $4.4M | 193.8K | 0.8% | ▲+184% Added · +126K sh | |
| 38 | Tango Therapeutics Inc COM | $4.2M | 200.9K | 0.8% | ▲New New position | |
| 39 | Sensei Biotherapeutics Inc COM NEW | $4.2M | 132.9K | 0.8% | ▲New New position | |
| 40 | Relmada Therapeutics Inc COM | $4.2M | 597.4K | 0.8% | ▲New New position | |
| 41 | Erasca Inc COM | $3.9M | 239.9K | 0.7% | ▲New New position | |
| 42 | Johnson & Johnson COM | $3.8M | 15.4K | 0.7% | ▼−56% Reduced · −20K sh | |
| 43 | X4 Pharmaceuticals Inc COM NEW | $3.5M | 850.7K | 0.7% | ▼−5.3% Reduced · −48K sh | |
| 44 | Vaxcyte Inc COM | $3.4M | 59.1K | 0.7% | ▲New New position | |
| 45 | Whitehawk Therapeutics Inc COM | $3.2M | 939.4K | 0.6% | ▼−36% Reduced · −519K sh | |
| 46 | Helix Acquisition Corp III USD CL A ORD SHS | $3.1M | 305.0K | 0.6% | ▲New New position | |
| 47 | Tenax Therapeutics Inc COM NEW | $3.0M | 188.7K | 0.6% | ▲New New position | |
| 48 | Alkermes PLC SHS | $2.8M | 80.5K | 0.5% | ▲New New position | |
| 49 | Pharvaris N V COM | $2.4M | 86.6K | 0.5% | ▲+48% Added · +28K sh | |
| 50 | Invivyd Inc COM | $2.4M | 1.87M | 0.5% | ▲+89% Added · +885K sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | SCHOLAR ROCK HOLDING CORPSRRK | $588K | 100K |
| PUT · bearish | REVOLUTION MEDICINES INCRVMD | $525K | 100K |
| CALL · bullish | TYRA BIOSCIENCES INCTYRA | $290K | 100K |
| CALL · bullish | IMMUNOVANT INCIMVT | $255K | 100K |
| CALL · bullish | SS SPDR S&P BIOTECH ETFXBI | $164K | 150K |
| CALL · bullish | SYNDAX PHARMACEUTICALS INCSNDX | $90K | 150K |
| CALL · bullish | SS SPDR S&P 500 ETF TRUST-USSPY | $86K | 50K |
| CALL · bullish | INVESCO QQQ TRUST SERIES 1QQQ | $74K | 40K |
| CALL · bullish | BOSTON SCIENTIFIC CORPBSX | $13K | 250K |
| CALL · bullish | TERNS PHARMACEUTICALS INC430 | $8K | 100K |
| CALL · bullish | OLEMA PHARMACEUTICALS INCOLMA | $4K | 25K |
| CALL · bullish | EDWARDS LIFESCIENCES CORPEW | $1K | 10K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 18, 2026 | 84 | $522.3M | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 78 | $583.2M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 90 | $499.1M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 54 | $311.6M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 62 | $313.7M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 58 | $400.6M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 13, 2024 | 58 | $334.0M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 13, 2024 | 44 | $340.3M | 13F-HR/A |
| Q1 2024 | Mar 31, 2024 | Aug 9, 2024 | 63 | $378.3M | 13F-HR/A |
| Q4 2023 | Dec 31, 2023 | Feb 13, 2024 | 70 | $374.8M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.